Glaucoma risk for oral contraceptive users

Women using oral contraceptives for 3 years or more may be at risk for developing glaucoma and should be screened for the eye disease if they have additional risk factors, according to researchers at the American Academy of Ophthalmology annual meeting in New Orleans. » Full article

FDA approves new athlete’s foot treatment

FDA has approved luliconazole (Luzu Cream, 1%, Valeant Pharmaceuticals) for the 1-week, once-daily treatment of interdigital tinea pedis, tinea cruris, and tinea corporis, caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients aged 18 years and older. » Full article

Analgesic overuse may worsen chronic headache associated with concussion

Excessive analgesics use can contribute to the chronic headache associated with concussion in some adolescent patients and discontinuing these drugs can improve symptoms, according to researchers at the 42nd Annual Meeting of the Child Neurology Society, in Austin, Texas. » Full article

Lurasidone effective in bipolar depression: Studies

Lurasidone HCl (Latuda) reduces depressive symptoms in adult patients with bipolar depression when used as monotherapy and adjunctive therapy to lithium or valproate. This flexibility is important given the multiple unmet needs of patients with bipolar depression, according to two phase 3 studies published recently in The American Journal of Psychiatry. » Full article

PODCAST: Hepatitis C overview

Listen to Eliav Barr, MD, vice president, infectious disease project and pipeline lead at Merck Research Laboratories in West Point, Pa., discuss with Formulary the cost burden of hepatitis C to the healthcare system, what to expect in the hepatitis pipeline in the near future, and the most effective way to manage these drugs on the formulary. » Full article

Continuing Education

New CPE mini-series: Multiple sclerosis

This month, Drug Topics offers the first of a two-part CPE series, "MTM considerations in multiple sclerosis." Earn up to 2 credits by completing this knowledge-based activity. To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.

Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

• Anti-seizure drug gets boxed warning of potential vision loss

• Cosmetic filler approved for adults with volume loss in cheeks

• Triptans widely prescribed for migraine but contraindicated in patients with CV conditions

• FDA approves vortioxetine to treat major depressive disorder

RESOURCES

Drug Watch

Latest Clinical News